Campylobacter jejuni is one of the most common causes of diarrhea worldwide. The gastrointestinal manifestations of Campylobacter infection range from watery diarrhea to severe dysentery. Campylobacter infection has also been linked to the postinfectious sequelae of reactive arthritis and Guillain-Barré syndrome. Evidence from epidemiologic and volunteer studies suggests that development of a vaccine to prevent gastrointestinal disease and limit colonization is possible. Efforts to develop live attenuated or subunit vaccines are limited by the finite knowledge of Campylobacter pathogenesis and lack of a conserved protective antigen, respectively. An oral killed, whole-cell vaccine has been shown to be safe and effective in animal models and is currently being tested in phase I volunteer studies.
Campylobacter jejuni is currently thought to be the most enteritis in children õ5 years of age is as high as 40,000/ 100,000, or 0.4 episodes per child per year [10, 11] . On the common cause of bacterial diarrhea in the United States and, basis of regional estimates of incidence, the annual number of on a global basis, probably ranks just behind enterotoxigenic patients developing Campylobacter diarrhea worldwide is a Escherichia coli (ETEC) as a leading bacterial cause of both staggering 400 million [12] . endemic and traveler's diarrhea (TD) [1 -6]. Because C. jejuni
As noted above, there is growing evidence that Campylois an important cause of TD, the US Department of Defense bacter species are second only to ETEC as a cause of TD has actively sponsored a Campylobacter research program [1, 13 -18] . Recent studies of Finnish travelers in Morocco headed by the US Navy. This program stresses basic pathogenfound that during the winter months, 28% of TD cases were esis research, and more recently it has expanded to applied attributable to Campylobacter infection, compared with only vaccine research and army-navy collaboration on clinical and 8% attributable to ETEC [14] . In other studies of civilian travelepidemiologic studies. This program is now testing a prototype ers, the percentage of TD cases with Campylobacter organisms inactivated, whole cell (WC) vaccine in volunteers.
isolated from their stools ranges from lows of 1% -3% in Mexico and 11% -15% in travelers to the Indian subcontinent to Epidemiology highs of 29% and 39% in travelers to Morocco and Thailand, respectively [1] .
Studies by the Centers for Disease Control and Prevention
Several studies have shown the importance of Campylobacter and a Seattle health maintenance organization found that species as a cause of TD in the US military. Navy vessels visiting Campylobacter species were isolated from diarrhea stools two port cities in South America, West Africa, and the Middle East to four times as frequently as were Salmonella or Shigella found Campylobacter species to be associated with 10%-20% species [2, 7 -9]. In developing countries, where hygiene and of the overall diagnosed diarrhea episodes, with isolation frequensanitation are lacking, an average child may have several severe cies ranging as high as 39% among cases following port visits diarrhea episodes per year, and the incidence of Campylobacter to some Latin American cities [19] The threat posed by Campylobacter-associated TD is exacer-
The opinions and assertion contained herein are the private ones of the author and are not to be construed as official or reflecting the views of the bated by the large percentage of isolates resistant to erythromyDepartment of the Navy, Department of Defense, or the US Government.
cin, the newer macrolides, and the fluoroquinolones [5, [20] [21] [22] Financial support: Naval Medical Research and Development Command and by the fact that Campylobacter-associated TD appears to S184 Scott JID 1997; 176 (Suppl 2) panying fever and abdominal cramps, which can be severe. serotypes examined, flagellin is not the Lior serodeterminant [47] . Animal studies have indicated that protection against inUntreated acute infection will most often run its course in 3 -5 days, followed by convalescent shedding of the organism testinal colonization, in at least one animal model, is Lior serotype specific [48, 49] . The lack of specific information on for several days to weeks [23, 24] .
Like Salmonella, Shigella, and Yersinia enteritis, Campylothe nature of the Lior serodeterminant and the large numbers of serotypes complicate vaccine development. However, several bacter enteritis has been associated with development of a reactive arthritis or arthropathy (RA) [25 -34] . Studies of outstudies indicate that a limited number of Lior serotypes predominate in different regions of the world [44] . For example, breaks [27, 32] and case series [28, 34] have found an incidence of rheumatic complaints ranging from about 1% to 14% in in Thailand, Ç75% of all isolates belong to 5 Lior serotypes (Bourgeois AL, personal communication). subjects with evidence of C. jejuni infection. However, these studies did not use a consistent definition of reactive arthritis
Campylobacter vaccine development programs must also consider the ability of this organism to cause RA and GBS. and included patients with joint symptoms, which in some cases lasted only 3 -7 days [28] . In most reported cases, sympHowever, epidemiologic studies to determine whether prior exposure to Campylobacter species will increase or decrease toms have resolved completely.
A less common but potentially more devastating complicathe risk of RA or GBS after a subsequent infection are lacking. Therefore, it is difficult to assess the impact that vaccination tion of Campylobacter infection is Guillain-Barré syndrome (GBS) [35 -37] . The association between GBS and Campylowill have on the incidence of these diseases. An effective vaccine will by definition prevent the clinical syndrome of Campybacter infection is supported by both serologic and culture data and will be discussed in other sections [35] . The occurrence lobacter enteritis but may not prevent colonization. Volunteer studies have shown clearly that colonization without disease of these postinfectious sequelae must be taken into account in the development of potential Campylobacter vaccines.
can induce both local intestinal and serum antibody responses [43] , which could potentially trigger postinfectious sequelae.
However if illness and intestinal tissue damage are required Campylobacter jejuni as a Target for Vaccine
for the infection to result in RA or GBS, then a vaccine that Development prevents illness would decrease the risk of RA and GBS. Also of concern is the potential for a Campylobacter vaccine, develData from epidemiologic and volunteer studies suggest development of an effective Campylobacter vaccine is feasible.
oped using any of the strategies discussed below, to cause RA or GBS. For RA, no bacterial factors have been identified as In the developing world, where Campylobacter infection is hyperendemic, disease occurs primarily in young children. Albeing causative. The risk of GBS after Campylobacter infection appears to be increased after infection with certain lipopolysacthough infection rates remain high throughout childhood, symptomatic infection rates are highest during the first year of charide serotypes and may be the result of human ganglioside mimicry [50 -55] . If the bacterial structures involved in induclife, followed by a marked decline in the ratio of symptomatic to asymptomatic infection [10, 38, 39]. Most infections are ing GBS can be clearly delineated, then it would be possible to construct even live attenuated vaccines that could be given asymptomatic in children §5 years old. In Mexico, Bangladesh, Africa, and Thailand, this apparent early acquisition of without a risk of GBS. immunity during the first 2 years of life has been shown to be accompanied by rising titers of Campylobacter-specific antiCampylobacter Vaccine Strategies bodies [39 -41] .
In a volunteer study, 7 people were made ill via ingestion It is widely believed that for a vaccine to be effective against an enteric agent, it must be able to stimulate intestinal immunity of C. jejuni 81 -176. One month later, the 7 subjects and 12 naive controls were challenged with the same isolate. None of [56 -59] . For this and logistical reasons, the oral route of immunization has been identified as the preferred approach in the the previously infected volunteers became ill, compared with 6 of the 12 controls [42, 43]. The organism was, however, able
Children's Vaccine Initiative [60] . It takes advantage of the tremendous amounts of lymphoid tissue in the oropharynx and to colonize both naive and previously challenged volunteers.
Development of a vaccine may be complicated by the treintestine and is simpler to administer than parenteral immunization. Several approaches to developing an oral vaccine are mendous antigenic diversity of the organism and by the fact that the protective epitopes are not clearly defined. The most possible.
Live attenuated vaccines. Live attenuated, oral vaccines common typing schemes are the Lior system, which includes 108 serotypes, and the Penner system, which has ú60 serotypes against 2 bacterial pathogens (Salmonella typhi and Vibrio cholerae) effectively stimulated mucosal immunity and pro-[44 -46]. The Penner or O serotyping system is based on lipopolysaccharide and lipooligosaccharide antigens; the serodetervided excellent protection in field or volunteer challenge studies [61 -63] . Using genetics to develop a live attenuated Campylominant of the Lior scheme is a heat-labile antigen, which was originally thought to be flagellin. Genetic analyses with sitebacter vaccine [64] is an attractive approach. This is complicated again by the paucity of information on pathogenesis and specific flagellin mutants, however, have indicated that in most S185 JID 1997;176 (Suppl 2)
Campylobacter Vaccines physiology of the organism. However, mutants of C. jejuni to produce and possess multiple antigens that can be important for protection. Formulations can be modified to offer protection 81 -176, which are nonvirulent in the ferret model because of either defects in invasion or pili biosynthesis, are being evaluagainst prevalent serotypes over time or in different geographic regions, as is done for influenza virus vaccines. Presentation ated in navy or Navy Medical Research Institute (NMRI) laboratories for their protective efficacy in animal models. The of multiple antigens may be particularly important for pathogens like Campylobacter species, for which protective antigens inclusion of a recA mutation [64] would preclude reversion to wild-type by this naturally transformable enteropathogen [65] .
are not known or not available in recombinant forms. Although less appealing for parenteral administration, these WC preparaIn addition to the attenuation of the organism, more must be learned about the mechanisms by which Campylobacter organtions are generally safe for mucosal immunization. [66, 67] . The overall structure of of the WC-BS vaccine conferred 85% protection against cholera for the first 6 months in all age groups tested and 51% campylobacter flagellins is similar to those of the Enterobacteriaceae, in that the amino and carboxy ends, which function overall protection after 3 years [77] . More recently, a new formulation of the WC-BS cholera vaccine containing a recomin the transport and assembly of the monomers into the filament, are highly conserved among different Campylobacter binant (r) BS (WC-rBS) was also found to be safe and give high levels of protection (protective efficacy Å 86%) against isolates, and the central region appears antigenically diverse [68] . Power et al. [68] have studied the antigenicity of Campysymptomatic cholera in Peruvian military recruits [78, 79] and 86% protection against ETEC diarrhea in Finnish travelers [80] . lobacter coli VC167 flagellin in detail and have shown that the major immune response seems to reside in the highly conserved
Although not as immunogenic as live attenuated V. cholerae vaccines [81, 82], these vaccines have proven that an orally amino and carboxy ends of the protein, areas which are not surface-exposed in the flagellar filament. In fact, the only suradministered WC vaccine can be safe and provide reasonable protection against an enteric pathogen. face-exposed epitopes identified were those that react with antibodies directed against posttranslational glycosyl modifications
The Enterics Program at NMRI has studied the hypothesis that a killed WC vaccine against Campylobacter species could [68 -70] . Moreover, a mutant defective in the ability to synthesize these glycosyl modifications loses the ability to protect be safe, immunogenic, and protect against disease, particularly if combined with an effective mucosal adjuvant, such as E. against strains of the same Lior serotype in the RITARD model [48, 71] , suggesting a role in the protective immune response coli heat-labile toxin (LT) [83] . Initial studies using C. coli VC167 showed that when sonicated cells were combined with for the modified flagellin but not the unmodified primary amino acids. The antigenic diversity of campylobacter flagellins, cou-25 mg of LT and given orally to mice, the mucosal immune response was equal to live infection with the same strain [84] . pled with the fact that these eubacterial proteins are glycosylated, may make the development of flagellin subunit-based
The duration of intestinal colonization after live challenge could also be significantly shortened in mice or rabbits immuvaccines highly problematic.
The other protein that has been suggested as a potential subunitnized with sonicates plus LT but not by immunization with sonicates alone. based vaccine target is PEB1, a highly immunogenic protein conserved among C. jejuni isolates [72] that has also been suggested More recent work using a mixture of heat-and formalinkilled C. jejuni 81 -176 in mice has shown that LT enhances to function as an adhesin to eukaryotic cells [72] . As more is understood about the pathogenesis of Campylobacter species, it the mucosal immune response over a wide range of vaccine doses [85] . Mice were orally immunized with three doses (at is likely that additional conserved subunit target proteins will be identified. One such candidate that was recently described are 48-h intervals) of either 10 5 , 10 7 , or 10 9 vaccine particles alone or in combination with 25 mg of LT. Significant Campyloperitrichous pilus-like appendages whose expression is induced in the presence of several bile salts [73] .
bacter-specific IgA and low levels of IgG were detected in intestinal lavage fluid only after immunization with adjuvanted Killed WC vaccines. Inactivated microorganisms offer several advantages as potential vaccines for mucosal immunizavaccine. In contrast, similar levels of Campylobacter-specific serum antibody levels were stimulated by WCs with or without tion. Physically, they are naturally occurring microparticles, which should enhance interactions between their surface and LT. The optimal secretory immune response was induced following vaccination with 10 7 of the Campylobacter killed WC mucosal lymphoid tissues. As vaccines, they are inexpensive S186 Scott JID 1997;176 (Suppl 2) (CWC)-LT formulation, suggesting the ratio of adjuvant to thersburg, MD, through a cooperative research and development agreement. The cells used for vaccine preparation were inactivated cells may be important. When challenged orally with live C. jejuni 81 -176, mice immunized with either 10 5 , grown under conditions that attempted to maximize motility and flagella expression and ability to invade eukaryotic cells 10 7 , or 10 9 WCs plus LT showed colonization resistance, whereas only the highest dose of CWC alone (10 9 cells) gave in vitro; the cells were inactivated by use of 0.2% formalin. The final preparation had intact flagella, as determined by electron comparable protection. Both vaccine formulations provided similar levels of protection against systemic spread of challenge microscopy, and retained its ability to agglutinate in Lior 5 antisera. organisms [85] .
In follow-on experiments, the relative protective efficacy and Volunteer studies of this vaccine are ongoing. They have shown that the vaccine is well-tolerated and moderately immuduration of immunity induced by CWC or CWC-LT vaccines were compared in an oral immunization -intranasal challenge nogenic (Scott D, unpublished data) . Studies combining the vaccine with a mucosal adjuvant have recently been completed, model [86] . Both CWC and CWC-LT formulations provided varying degrees of protection against illness and intestinal coloand a volunteer challenge study is planned for the near future. nization for up to 4 months after completion of the two-dose (14-day intervals) primary immunization series. However, the sponses to C. jejuni antigens were also measurably enhanced by the addition of LT.
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